Stem cell transplants that follow both myeloablative and non-myeloablative conditioning regimens can result in states of mixed chimerism, which can be stable over time.
Introduction
The chimera of Greek mythology was said to possess the head of a lion, the body of a goat and the hind part of a dragon. Despite these disparate components, the chimera was functional, able to spit fire and terrorize Asia Minor until it met its demise. 1 The term 'chimerism' as now applied to describe a state in which an organism possesses cells derived from two or more distinct zygote lineages, also has potential impact on function and survival of the organism. In the field of hematopoietic SCT, the ultimate effect of chimeric influences often remains unclear and may have different implications in varied disease settings. In this review, we discuss the impact of mixed donor chimerism on transplant outcomes.
The measurement of chimerism
Chimerism analysis is used to determine the genotypic origin of post transplantation hematopoiesis. Hematopoiesis can be of 100% donor origin, a state called 'complete chimerism' or coexisting donor and recipient origin, a state called 'mixed chimerism'. 2 In the past, chimerism could be measured with multiple methodologies including cytogenetics (routine banding or FISH for Y chromosome in sex-mismatched transplants), red cell phenotyping in cases of ABO or Rh incompatibility and RFLPs, all with limitations (reviewed recently in Bone Marrow Transplantation by Bader et al. 3 ). Currently, the most frequently used methods for the measurement of chimerism are X and Y chromosome FISH for gender-mismatched transplants and DNA-based methods for the remaining allogeneic transplants. Early work on the use of DNA to monitor engraftment made use of RFLPs and variable number of tandem repeat (VNTR) polymorphisms detected using Southern blot hybridization methodology. 4 Southern blots require a fairly large quantity of DNA, take several days to complete and consume quite a bit of technical time. For these reasons coupled with a relative insensitivity limited to about 5-10% residual recipient hematopoiesis, Southern blots have been abandoned in favor of techniques based on the PCR. PCRbased techniques are much faster, allowing more rapid generation of results, and require less DNA, allowing evaluation of chimerism at an earlier time after transplant when the BM is still hypocellular.
The strategy in chimerism analysis is to first find a unique DNA fragment in both the donor and the recipient. It is important that a specimen is obtained from the recipient prior to transplant to facilitate this task. If the post transplant marrow DNA lacks the donor-specific fragment, it indicates graft rejection or graft failure. The recipient-specific fragment is important because it is a marker of the pre-transplant hematopoietic system. Sensitive detection and measurement of the recipient-specific DNA allow sensitive measurement of residual recipient hematopoiesis. The preferred polymorphisms for analysis are short tandem repeats of about four to five nucleotides in length. These VNTR polymorphisms have multiple alleles compared with the two alleles for RFLPs. Therefore, not as many polymorphic systems are needed to find unique markers for the recipient and the donor. Most labs amplify the DNA using a fluorescent dye attached to one of the primers. After PCR, the DNA fragments are resolved by size using capillary electrophoresis and quantified by their fluorescence. The relative amplification of the alleles in a VNTR polymorphism is frequently skewed to increased signal from the smaller form. Accurate quantification of the relative amount of donor and recipient can be recovered with the use of a standard curve constructed using mixtures of donor and pre-transplant recipient DNA. Interpolation of the post transplant results on this curve corrects for most PCR artifacts. The preferential amplification of smaller PCR products can be exploited to increase the analytical sensitivity for the detection of residual recipient hematopoiesis. In most cases, the sensitivity limit of this methodology is around 1% for the smaller cell population. A recent detailed review of this methodology is provided by Bader and Kreyenberg. 5 Some laboratories have successfully adapted commercially available multiplexed PCR systems that were originally designed for forensic use to chimerism analysis. 6 Most recently, real-time quantitative PCR (Q-PCR) has been applied to the study of chimerism. 7 This methodology is capable of increasing the analytical sensitivity for the measurement of the smaller cell population by 1 to 2 orders of magnitude so that one cell in a thousand or even one cell in ten-thousand can be detected. The Q-PCR method can also speed up the analysis so that results are obtainable in a few hours. However, at higher levels of mixed chimerism, the Q-PCR method is less accurate than the measurement of fluorescent VNTR polymorphic fragments.
One of the hazards in any DNA-based method for the measurement of chimerism after allogeneic transplant for a hematopoietic malignancy is a relapse that lacks the unique recipient-specific target due to deletion or aneuploidy. This would make the increase in recipient blood cells invisible to analysis. 8 To avoid this situation, it is desirable to target two polymorphic systems on different chromosomes.
It is important that the testing laboratory is provided with pre-transplant blood specimens from both the donor and the recipient. This allows the laboratory to plan the strategy that will be used for analysis of post transplant specimens. If the pre-transplant recipient specimen is not obtained, it is still possible to plot a strategy using alternate specimens to determine the recipient genotype. Figure 1 shows such an analysis. It is important to note that the post transplant buccal DNA from the recipient contained a large fraction of signal from the donor. This is a common finding that is due to the presence of hematopoietic cells in the buccal sample and also due to donor chimerism in the epithelial cells.
9,10 Some laboratories have had success obtaining pure recipient DNA from fingernails, but even this source is eventually mixed with donor DNA in many patients after allogeneic transplant. 11 Several other tissues, including epithelial cells of the colonic mucosa and liver, and even neurons in the brain, have been shown to become chimeric after allogeneic stem cell transplant. [12] [13] [14] Hair follicles have been found to contain DNA that has a 100% recipient genotype, which may serve as a reliable source of recipient origin DNA when pre-transplant specimens are not available. 15 Still it is best to obtain a pre-transplant blood specimen from the patient so that an adequate supply of DNA is available for constructing standard curves.
Chimerism at a single-cell level can also be measured by the expression of HLA molecules. This can be helpful in the determination of chimeric status in cases of HLA-mismatched transplant; for example between Bw6 and Bw4 or   2000  1800  1600  1400  1200  1000  800  600  400  200  0   200  220  240  260   200  220  240 specimen. The genotype of the recipient was determined using DNA from a buccal swab (top panel), and compared with DNA from the donor's blood (middle panel). The alleles from the buccal DNA (11 years post transplant) that are not from the donor are from the recipient, and are indicated by asterisks (*) in the figure. After transplant, only donor-specific alleles are seen in the blood (bottom panel). The lack of a pure recipient pre-transplant DNA made it difficult to estimate the sensitivity of the analysis using mixtures of donor and recipient DNA. In all of the graphs in Figures 1-5 , the Y-axis is fluorescence intensity in arbitrary units and the X-axis is the size of the fragment in base pairs.
other serologic Ags. This has a sensitivity of detection of 0.1%. 16 For analysis of chimerism in lineage subsets, cell sorting by flow cytometry or by selection with Ab-coated magnetic beads can be utilized. These analyses involve added steps of sample manipulation to isolate various components of the mononuclear cell fractions and increase the time and labor needed to complete the assay. In addition, a larger initial specimen is needed to obtain sufficient DNA for analysis of smaller subpopulations. Generally, anti-CD3 Abs are used for T-cell identification and separation, anti-CD19 for B cells, anti-CD33 for myeloid cells and anti-CD56 for NK cells, but other markers are also available and utilized for these purposes. 17 Anti-CD105 can be used to select BM stromal cells for chimerism determination. 18 What level of analytical sensitivity is optimal for chimerism analysis? The use of Y-chromosome PCR is capable of sensitivity down to 0.1-0.01% recipient DNA. The use of this system has shown that very low levels of recipient cells, below 1% of total nucleated cells, were a common and transient phenomenon that did not correlate with an increased incidence of relapse. [19] [20] [21] However, only a limited number of patients have been studied with this type of sensitivity. The recent availability of real-time PCR methods for chimerism analysis will allow the issue of optimal analytical sensitivity to be addressed in a larger number of patients under more diverse clinical circumstances.
Situations in which chimerism analysis may be inaccurate or uninformative post transplantation include rare cases of unintended engraftment from transfusions, aneuploidy causing deletion/duplication of a polymorphic band as mentioned above and limitations of the tissues that can be studied (for example, central nervous system relapse that would not be detected with marrow and blood chimerism examination).
Sensitive methodologies for the detection of chimerism have demonstrated the presence of mixed chimerism in many settings post transplantation. The significance of this finding has different weight depending on the disease for which the transplant was performed, the type of graft utilized, time from transplant and cell type(s) demonstrating mixed chimerism.
The role of mixed chimerism in non-malignant diseases
In non-malignant disorders, it is believed that complete replacement of the recipient's hematopoietic system is not necessary to improve the underlying disease state. For this reason, non-myeloablative or reduced intensity conditioning is sometimes used, although this results in graft rejection or nonengraftment in some cases.
In the hemoglobinopathies, the rapid development of complete chimerism in the NK cell and T-cell lineages is thought to play a role in achieving sustained engraftment. In thalassemia transplants where ablative conditioning regimens were utilized, some transplant groups have reported that more than 30% recipient mixed chimerism correlated with rapid graft rejection. 22 In another series, the incidence of mixed chimerism at 2 months after transplantation was 32.2%. None of the 227 cases with complete chimerism rejected their grafts, whereas 35 out of 108 with mixed chimerism lost their grafts. 23 There does appear to be a potential positive role for stable mixed chimerism in some thalassemia cases, however, as demonstrated in the series cited above where out of 335 patients, 34 cases developed persistent mixed chimerism beyond 2 years. In some of these cases, the percentage of recipient cells was greater than 25%, but despite this, patients remained transfusionindependent and without evidence for disease recurrence. This appeared to be correlated with a state of tolerance, and graft rejection was unlikely once stable mixed chimerism was established. 23 There is evidence in sickle cell disease that even a small degree of mixed chimerism can prevent intravascular hemolysis. 24 It has been reported that 10% donor engraftment is necessary for the effective treatment of HbSS disease in cases transplanted with stem cells from a HbAA donor, whereas a level of mixed chimerism as high as 30-50% may be necessary in patients transplanted from a donor with sickle cell trait. 25 In patients with sickle cell disease and stable mixed chimerism, there is evidence that ineffective erythropoiesis in the HbSS progenitors provides a maturation advantage for HbAA or AS donor erythroid precursor cells, consequently resulting in a disproportionately greater donor contribution to red cell production. 26 Analysis of chimerism in immature and more mature erythroblasts showed that SS erythroblasts were destroyed in the marrow with increased maturation. 26 In the US Multicenter Study where patients with sickle cell disease received transplants from siblings after ablative conditioning, 5 of 44 patients developed sustained mixed chimerism post transplant. Two recipients of transplants from Hgb AA donors with donor predominant engraftment had peripheral quantitative HbS levels of 0%. A third recipient of a transplant from an Hb AA donor with only 11% donor engraftment had a peripheral quantitative Hb S level of 7%, reflecting donor RBC enrichment attributable to longer survival. Two patients who received transplants from sickle trait donors and had host-predominant hematopoiesis still had Hb S levels under 50%. Significantly, with median follow-up of 17 months, none of these individuals had acute manifestations of sickle cell disease. 25 Those recipients who demonstrate mixed chimerism after transplantation for hemoglobinopathies such as sickle cell disease are more likely to reject their grafts. 27 Graft rejection can be avoided in cases with serial increases in recipient contribution to chimerism with graded donor lymphocyte infusions. It has been reported that the use of anti-thymocyte globulin markedly influenced rejection rate; 22.6% before its use and 3% after with an overall survival of 93% and EFS of 86.1% in one series of myeloablative transplants. 27 Anti-thymocyte globulin has also been incorporated into non-myeloablative transplants for sickle cell disease. 28 Similarly, Campath has been incorporated into preparative regimens to achieve greater immune suppression. 25 When immunosuppression is withdrawn after the establishment of donor myeloid chimerism, graft rejection has often been observed, suggesting that stable mixed chimerism is difficult to achieve in some of these immune-competent patients even when anti-thymocyte globulin is used in the conditioning regimen. 28 
Mixed chimerism in SCT JL Liesveld and PG Rothberg
In aplastic anemia, mixed chimerism has also been associated with graft rejection. Some investigators recommend donor leukocyte infusions (DLI) when autologous cells reach 430%, but this has attendant risk for GVHD. A case that illustrates the implications of mixed chimerism in aplastic anemia is that of a 22-year-old female with a several year history of aplastic anemia transplanted with marrow from her 10/10 HLA-matched brother. She was conditioned with CY and horse anti-thymocyte globulin and received 4 Â 10 6 /kg marrow CD34 þ cells. She had rapid, robust engraftment but 8 months after transplantation, she had a rapid fall in blood counts and presented with sepsis and a central nervous system bleed. The chimerism pattern, determined using Y chromosome FISH analysis, is shown in Table 1 . She was reconditioned with rabbit antithymocyte globulin (ATG) and fludarabine and had a second stem cell infusion, this time with mobilized peripheral blood stem and progenitor cells (PBSCs) from the same sibling with the total CD34 þ cell number of 7 Â 10 6 /kg. Complete donor chimerism was rapidly achieved, and the recipient's blood counts have remained normal for more than 12 months after the second stem cell infusion. Whether the stability of the second graft was due to increased numbers of CD34 þ cells infused, different numbers and type of T cells infused, alteration of the conditioning regimen to include fludarabine or due to other host factors remains uncertain.
In other inherited and acquired bone marrow failure disorders, 10-20% donor cells can improve disease status, and it appears that stable mixed chimerism at this level is an acceptable outcome, but an increasing level of recipient cells often precedes graft rejection. 3 This appears to be a recurring theme regarding mixed chimerism in nonmalignant marrow disorders. The components contributing to the chimera can remain in balance for a while but once the newest component of donor origin starts to lose its battle for contribution to hematopoiesis or immunologic function, that part of the organism is at risk for being rejected. Despite the tendency to reject the relatively new donor component, mixed chimerism can become a stable state. For example, a case of prolonged mixed chimerism in a patient with severe aplastic anemia, which demonstrated a full recovery in hematological and immunological status after transplantation, has been reported. 29 In cases of mixed chimerism in non-malignant disorders, the degree of contribution of each component to the mixed chimeric state is neither always an accurate predictor of the ultimate stability of the state nor is it well understood what immunologic components are required for tolerance induction and preservation of contributions to hematopoiesis or immune function.
The role of mixed chimerism in malignant diseases
Mixed chimerism in transplants performed for malignant disease can herald the reappearance of malignant cells of recipient origin. Determining whether this reflects appearance of normal host hematopoietic cells or of leukemia or lymphoma cells is often difficult to discern solely from chimerism studies unless cell separation techniques are utilized which allow the distinction of myeloid vs lymphoid chimerism. In both CML and AML, reappearance of host hematopoietic cells in the mononuclear cell fraction often precedes hematological relapse, but more sensitive techniques that measure minimal residual disease directly using a marker of malignancy are more likely to be predictive, when such a marker is available. Because the most commonly used chimerism assays have a sensitivity of about 1% for residual recipient cells, they are less sensitive than molecular markers that can achieve sensitivities down to 0.01% and even lower. For AML, chimerism is most predictive when examined in CD34 þ hematopoietic cells. 30 In all cases of transplantation for acute leukemias, if relapse is to occur, the time between mixed chimerism detection and overt relapse can be so short as to preclude any meaningful clinical knowledge or action that could stem from this knowledge. In one series, patients with a high risk of relapse were found to have decreasing donor chimerism between days 28 and 175 after transplantation, and donor chimerism in CD34 þ cells decreased 2-50 days earlier in those patients who relapsed. 31 At relapse of AML, 29-98% donor chimerism in lymphoid and myeloid cells was found but only 20% donor chimerism in the CD34 þ fraction. 31 In another series of 30 patients analyzed 1 month after allografting, 14 of 30 patients had mixed chimerism. Ten out of the 14 patients with mixed chimerism relapsed compared with only 2 of the remaining 16 patients with complete donor chimerism. Mixed chimerism was detected a median of 66 days before hematological relapse (range 23-332) days. There was no correlation between T-cell mixed chimerism and relapse; only lineage-specific chimerism was predictive; for example, CD33-, CD7-or CD45-positive cell populations. 32 In another series that evaluated chimerism as a predictor of relapse in AML, 33 VNTR PCR was used to determine chimerism in T-and non-T-cell subsets, and to retrospectively evaluate clinical outcome in 96 cases; 43 out of 96 patients relapsed in this series. The last chimerism evaluation before relapse revealed increasing mixed chimerism in only eight patients. In samples taken between 1 and 6 months after SCT, complete chimerism or decreasing mixed chimerism was significantly related to a lower risk of relapse (31 vs 83%; Po0.001). Because of the rapidity of relapse, chimerism was not found to be of help in the prediction of relapse. Figure 2 represents an example of a case of AML transplanted from an unrelated donor after BU and CY conditioning where increasing donor chimerism paralleled disease relapse and also paralleled response to reinduction but did not aid in determining early relapse. In some chronic malignant disease states such as CML, chimeric state can be reflective of disease relapse but is rarely helpful in the presence of good minimal residual disease markers such as Q-PCR for BCR-ABL fusion gene expression. In CML and Philadelphia chromosome-positive ALL, imatinib or dasatinib is able to restore full donor chimerism after relapse subsequent to unrelated donor transplantation. 34 Therefore, following quantitative BCR-ABL and chimerism may have some clinical utility, especially in situations where decisions must be made regarding the use of DLIs for the treatment of relapse with attendant risks of GVHD. It should also be kept in mind that relapse in various forms of leukemia can occur with 100% donor chimerism in marrow or blood, the relapse often occurring in extramedullary sites. 35 Mixed chimerism in non-myeloablative a stem cell transplants It has been known for a long time that the degree of host immune suppression plays a role in chimerism induction. For example, etoposide and cytarabine are inferior to CY in their rejection-preventing potential. 36 In non-ablative stem cell transplants where the conditioning regimens are immune suppressive but not marrow ablative, mixed chimerism may persist for the first 6 months, and was originally expected in these transplants to be of use as a platform for immune modulation to enhance antitumor effects with minimization of regimen-related toxicity. The impact of mixed chimerism at various time points after a non-myeloablative transplant is not fully appreciated yet, even though it is thought to be associated with a trend toward increased relapse. If the transplant was performed for a myeloid malignancy, it was recommended to examine myeloid, T cell and NK cell compartments individually. DLIs can be used in these settings to convert mixed to full donor chimerism but at the risk of GVHD and graft rejection. 37 When the use of marrow or G-CSF-mobilized PBSC in a setting of uniform non-myeloablative conditioning was compared, neutrophil and platelet recovery were faster in PBSC recipients. Marrow recipients (48%) achieved full donor chimerism with a median time of 34 days, and some required DLI to achieve this. In 83% of the PBSC group, full donor chimerism was noted at a median of 14 days. The rates of acute GVHD were comparable. CD4 and CD8 recovery was improved with the PBSC grafts. 38 The kinetics of CD3 þ T cell chimerism after non-ablative transplantation may also have implication for incidence and severity of GVHD. Mohty et al. 39 found that those with full donor T-cell chimerism at day 30 had a higher incidence of grades 2-4 acute GVHD compared with mixed T-cell chimerism cases. In another series, 40 where fludarabine/BU conditioning was used, T-cell full donor chimerism was observed (over 90%) in 22 of 30 patients, whereas the remaining had mixed donor chimerism by day 90. Five more patients were converted to full chimerism by days 120-280, and two patients had persistent mixed chimerism without disease relapse through day 180. It was therefore postulated that satisfactory antileukemia effects could be obtained regardless of the early chimerism state. In other series, however, achievement of full donor chimerism was associated with a decreased risk of progression or relapse, 41 and this decrease was also positively correlated with the incidence of extensive chronic GVHD.
Although 100% donor chimerism is often the goal in nonmyeloablative transplants, if a stable mixed chimerism occurs, that state might potentially be associated with adequate graft-vs-malignancy effect to obviate need for achievement of full donor chimerism. However, little data about this prospect exists. In most of these cases, the impact of mixed chimerism much beyond 6 months after the withdrawal of post transplant immune suppression is not yet fully appreciated. The difficulty of using mixed chimerism in the absence of GVHD as a trigger to prophylactic DLI administration is that full donor chimerism is often achieved with significant GVHD risk, and graft failure can occur if the donor T-cell chimerism was o20%.
42
In most transplant settings, engraftment failure occurs unless recipients are subjected to cytotoxic or immune suppressive pre-conditioning. It has been found that with the use of ACK2, an inhibitor of c-kit function, more than 98% of endogenous hematopoietic stem cells are removed in immunodeficient mice. When donor hematopoietic stem cells are infused, up to 90% donor chimerism occurs. 43 Whether this type of approach might have eventual application in human stem cell transplants to achieve chimeric states without cytotoxic or other immune suppressive chemotherapies remains unexplored.
Effect of graft type on incidence of mixed chimerism
T-cell-depleted grafts are associated with increased incidence of mixed chimerism. Certain types of T-cell depletion such as CD6 depletion have been associated with stable mixed chimerism. 44 CD34-selected grafts can also be associated with mixed chimerism, a state which may not be reversed by add back of T cells. 45 Also, the incidence of mixed chimerism after cord blood transplantation following reduced intensity conditioning regimens is incompletely defined. 46 Complete chimerism usually occurs after cord blood transplantation with ablative conditioning regimens, and there are reports of absent donor engraftment at 4 weeks after transplant with later appearance of complete donor chimerism. 47 The importance of lineage-specific mixed chimerism
Myeloid chimerism
After allografting in CML, in some cases, less than 10% erythroid and up to 16% host megakaryocytes can be identified. This was established by simultaneous immunophenotyping and genotyping with sex-chromosome-specific DNA probes. 48 This did not appear to have an impact on disease relapse.
NK cells
The alloreactivity of NK cells is mediated through the interaction of their killer Ig-like receptors (KIRs) with target cell HLA/Kir ligands. Sobecks et al. 49 examined 31 T-cell replete-related donor non-myeloablative transplants using fludarabine and TBI conditioning. Patients with fewer recipient inhibitory KIRs that could be engaged with donor HLA/Kir ligands were less likely to achieve T-cell complete donor chimerism, and were more likely to develop graft rejection than those with more engaged KIR receptors. It was postulated that these patients might have more active anti-donor immune effector cells resulting in reduced donor chimerism. 49 Davies et al. 50 examined class I mismatches with and without Kir ligand incompatibility. It was found that donor vs recipient NK cell alloreactivity could eliminate leukemia relapse and graft rejection, and protect against GVHD. It was postulated that the presence of donor alloreactive NK cells should eliminate host APCs and host tumor cells. It has also been noted that anti-NK cell treatment can induce stable mixed chimerism in MHC-mismatched, T-celldepleted, non-myeloablative BMT. 51 
Stromal cells
The origin of stromal cells and fibroblasts in the BM after allogeneic transplantation has long been a source of controversy. It has generally been found that fibroblasts of recipient origin remain, but some endothelial progenitors that are CD34 þ may be transplanted and may establish chimerism in various vascular beds. 52 Donor multipotent mesenchymal stromal cells may also engraft after cord or marrow transplants, 53 and such engraftment has also been found after non-myeloablative transplants with either marrow or mobilized peripheral blood grafts. 54, 55 In these cases, monocyte/macrophage or other cell contamination is often difficult to guard against. It is presumed that these mesenchymal stem cells are transferred in the graft. 56 Other studies have shown that mesenchymal stem cells of recipient genotype remain despite complete hematopoietic chimerism. 57 Also, there may be differences in propensity for mixed chimerism to appear based on disease type for which the transplant was performed. In myelofibrosis, the endothelial cells maintain recipient origin, whereas CD34 þ endothelial cell progenitors were found to be of donor origin in some cases. 58 Some donor-derived endothelial progenitor cells were probably present to account for minimal mixed chimerism of the stromal compartment. Other groups have also shown mixed chimerism of BM vessels (endothelial cells and myofibroblasts) after allogeneic transplantation for CML. 59 In some diseases, host stroma may limit the amount of donor chimerism that can be achieved. In osteogenesis imperfecta, 60 clinical benefit occurred after allogeneic transplantation, but the osteopoietic engraftment seemed saturable at about 15% of all bone cells in the epiphysis and metaphysis of the femur at 3 weeks after transplantation. There was no evidence that transplanting more progenitors increased this degree of engraftment.
DCs
In contrast to other DCs, host Langerhans cells were found in a murine model to be replaced by donor Langerhans cells only when donor T cells were given along with a marrow transplant. Donor T cells triggered a Fas-dependent pathway and induced CCL20, resulting in recruitment and apoptosis of donor Langerhans cells. 61 As host Langerhans cells are thought to induce skin GVHD through activation and effector phases, it was postulated that in mice, host DCs could therefore persist and trigger GVHD despite complete blood chimerism. 62 Liver, blood and lymphoid organ DCs were all of donor origin within 3 to 4 weeks, but host Langerhans cells could persist in the absence of donor T-cell engraftment. In eight children with MHC class II deficiency (bare lymphocyte syndrome) transplanted with allogeneic BM, T-cell-depleted grafts did not replete MHC II þ Langerhans cells in the skin but whole allogeneic marrow did, suggesting that this process may also be meaningful in humans with regard to GVHD potential. 63 
T cells
Although the goal of most transplants is to achieve nearly total donor chimerism, in some cases, stable low levels of donor chimerism may be acceptable and even beneficial. For example, in adenosine deaminase (ADA)-deficient severe combined immune deficiency, transplantation is performed without prior cytoreductive conditioning. Only 1-3% of lymphocyte and myeloid cells are of donor origin and there is no selective expansion of donor-derived lymphocytes. The restoration of immune function occurs by rescue of endogenous ADA-deficient lymphocytes through cross-correction from the engrafted ADA-replete donor cells. 64 The importance of T-regulatory cells (T-regs) in chimeric states is still being investigated. The CD4 þ CD25 þ population of T cells from splenocytes of chimeric mice was found to inhibit HY-specific CD3 þ T-cell responses in vitro and in vivo. Recipient T-regs were required for the generation but not for the maintenance of host-vs-graft tolerance. 65 Donor-specific T-regs of recipient origin are recruited when donor Ags are present during reducedintensity conditioning which may induce T-reg expansion. 66 In mice with established leukemia or lymphoma, CD4 þ CD25 þ regulatory T cells have been found to suppress ability of alloreactive donor T cells to induce GVHD without adversely affecting their graft-vs-tumor function. 66 The contribution of these cells to states of tolerance and GVHD in human transplants continues to be explored. 
Examples of cases in which the implication of mixed chimerism is uncertain
Stable mixed chimerism after reduced intensity transplantation for Hodgkin's lymphoma In some cases of mixed chimerism after SCT, the significance of the mixed chimeric state remains uncertain when examined at isolated time points in an individual patient's course. What will be the final contribution of the chimera to graft-vs-malignancy, stable hematopoiesis or risk for GVHD once immune suppression has been tapered or discontinued? What level of chimerism is ideal for each of these processes and in each type of disease for which transplantation is performed? An example of stable mixed chimerism over a 1-year period is that of a 34 year female with Hodgkin's lymphoma who underwent a reduced intensity marrow stem cell transplant from an unrelated donor. She had been diagnosed 6 years prior and had undergone an autologous stem cell transplant at first relapse. Relapse after Auto-SCT was treated with several salvage chemotherapy regimens before allogeneic SCT, during which she was conditioned with fludarabine, BU and rabbit anti-thymocyte globulin, and thereafter received 3.45 Â 10 6 peripheral blood CD34 þ cells per kg from a 9/10 HLAmatched ABO compatible unrelated female donor. The HLA mismatch was at the C locus. Neutrophil engraftment was delayed until day 28, reached a normal level at day 35, but then started to fall again. Platelet transfusion dependence persisted. No GVHD has occurred, and immune suppression has been tapered with no effect on blood counts or donor chimerism. Donor contribution to overall chimerism has remained stable at about 70% since day 100 with minor variation as measured in both marrow and blood. As shown in Figure 3 , when lineage-specific chimerism was analyzed at 11 months after transplant, both B-cell and myeloid (non-B, non-T) chimerism were at about 70% donor, whereas T-cell chimerism was predominantly recipient. The WBC count normalized, but infrequent red cell and platelet transfusion dependence persisted. The BM is mildly hypocellular, with no evidence for recurrence of the Hodgkin's lymphoma.
This case illustrates that it is sometimes difficult to distinguish between secondary graft rejection and stable mixed chimerism. In the setting of a non-ablative transplant, the issue of whether to treat with DLIs or additional stem cells with the intention of achieving full donor chimerism to promote a graft-vs-tumor effect and improved hematopoiesis but with increased risk of GVHD is raised. How much lymphoid chimerism is enough to achieve a graft-vsmalignancy effect? It is also difficult in these cases to predict the effects of taper or discontinuation of immune suppression because agents such as tacrolimus, cyclosporine and mycophenylate mofetil are no doubt serving the dual purposes of antirejection as well as GVHD prophylaxis. In many of these cases, as the GVHD prophylaxis regimen is tapered, only frequent analysis of chimerism will help to discern whether the mixed chimerism is stable or whether a rejection process is active.
Cases of multiple cord blood donors
In cord blood transplantation in humans where dual cord donors are used, one of the grafts usually predominates after time, leading to mixed chimerism or full donor chimerism vs trichimerism. 68 Figure 4 illustrates two cases of dual cord blood transplantation, in one of which (a) both cords contribute to early post transplant BM chimerism with one cord predominating, and the other (b) only one cord was seen to contribute to post transplant chimerism in the peripheral blood at all times measured. In a canine model, it has been found that after nonmyeloablative conditioning, transplantation of marrow grafts from two DLA-identical littermates concurrently can result in trichimerism over time, and immunologic tolerance could be demonstrated to a renal graft from one of the marrow donors. 69 The measurement of chimerism after transplant with two cord blood donors presents special problems to the laboratory. It is not feasible to construct a three-way standard curve. Our practice is to employ a polymorphic system in which the donors are identical and there is a unique recipient allele, when such a system is available. Then a single standard curve can be used to assist in quantifying chimerism. This situation is not common. In the remaining cases, we select polymorphic systems that distinguish all three genotypes and estimate chimerism without the use of a standard curve. When one of the donors becomes predominant then the situation simplifies and a standard curve with the surviving donor can be used.
Blood vs marrow chimerism
During the first 3 months after transplant for myelofibrosis, the marrow will have 30-40% recipient cells with a tendency to decline after about 1 year. PCR analysis of peripheral blood may show full donor chimerism during these same time points. 70 There are also situations wherein chimerism assessment may differ between marrow and blood, and this can often be an indication of disease relapse in marrow. Figure 5 demonstrates an example of disparity between marrow and blood chimerism in a case of a myeloproliferative syndrome treated with an allogeneic stem cell transplant in which fibrosis persisted after the transplant.
When to start measuring chimerism
Analysis of chimerism at very early time points has demonstrated the emergence of donor-specific alleles in peripheral blood as early as 3-7 days after allogeneic transplantation. 71 This was thought to indicate early stable engraftment and also to identify patients at risk of graft failure or relapse, but this has not been substantiated in large transplant groups. There are recommendations that chimerism be checked weekly for the first 100 days, but again, in many situations, transplant physicians will have few options to act on information provided. 3 Although early measurement of chimerism may monitor engraftment, it is uncertain that it will truly monitor propensity for ultimate graft rejection or that it can help in identification of early relapse. In one study of AML patients who had stable or increasing mixed chimerism, 10 of 32 patients were given DLI, and all relapsed despite this, suggesting that other strategies will be needed to deal with rapid relapse or that shortening of chimerism monitoring intervals may be needed. 72 There are some studies that suggest that after reduced intensity conditioning regimens for AML and MDS, which contain alemtuzumab, attainment of early full donor T-cell chimerism may be associated with higher TRM. 73 Although several groups have made recommendations about when and how frequently to monitor chimerism, more studies are needed to validate the impact that such monitoring has on transplantation outcomes. 17 Use of mixed chimerism to induce tolerance Transplantation of hematopoietic stem and progenitor cells is one of the best ways to induce tolerance. Robust tolerance is evident in mixed chimeras. 74 They permanently accept donor skin grafts while promptly rejecting thirdparty grafts. For this reason, marrow transplantation is an efficient approach to develop donor-specific tolerance and to prevent chronic rejection. Expression of chimeric Ags in the thymus can modify the generation of specific T-cell clones and this could be of importance in the induction of central tolerance against foreign Ags important in allotransplantation. 75 For this reason, concurrent blood or marrow SCT has been used in the setting of solid organ allografts as a means of tolerance induction. 76, 77 Strober 76 has reported on combined kidney and marrow transplants. The rationale is that host NK and T cells facilitate graft acceptance by recognizing CD1d on donor cells. In one study using this concept, 78 80 cGy TLI over 10 doses and 5 doses of rabbit anti-thymocyte globulin were given, and all recipients became complete chimeras after undergoing kidney and granulocyte CSF-stimulated blood SCT concurrently. The stem cell transplant was CD34 selected with T-cell add-back (1 Â 10 6 CD3 þ cells per kg). Stable mixed chimerism was achieved, both GVHD and organ graft rejection were avoided, and anti-rejection medications could be discontinued. 78 Allo-SCT with costimulatory blockade is also being explored as a means to induce mixed chimerism and tolerance. 79 Skin transplantation may also be a tool to monitor nonrelated tolerance in hematopoietic chimeras. This could be applicable in cases where subsequent sold organ transplantation from the same donor is contemplated. 80 
Summary
States of mixed chimerism can have varied significance depending on the underlying disease for which the transplant was performed, the conditioning regimen, the level of mixed chimerism, the trend in degree of mixed chimerism and the lineage of the cells assessed in the chimerism assay. Mixed hematopoietic chimeras can occur even though the pre-transplant regimen has included highdose chemotherapy and ablative TBI. For a long time, 81, 82 it has been known that some of these mixed chimeras may survive without disease recurrence, and most will have no or only mild GVHD. Although mixed chimerism can be achieved with less intensive conditioning regimens that greatly reduce the risk for post transplant organ toxicity and infections, there are little clinical data regarding the effect of sustained mixed chimerism on the risk of GVHD and graft-vs-tumor effects in these reduced intensity transplants. In some of these non-myeloablative transplants, mixed chimerism may indicate a tendency to graft rejection, but mixed chimerism is not always incompatible with sustained engraftment.
An absence of GVHD has been observed in murine and non-human primate models of transplant with sustained mixed chimerism. 83 The mechanisms of why this might be so remain undetermined. Certainly, reduced intensity regimens continue to be associated with significant transplanted for a myeloproliferative disorder, the first chimerism analysis after SCT showed complete donor chimerism in blood and persistent recipient chimerism in marrow. In some cases, this can indicate progressive or refractory disease, but in most cases of myelofibrosis or myeloproliferative disorders, it can indicate persistent but declining disease burden. The double peaks in the figure, separated by one nucleotide, are due to variable non-templated A addition by the Taq DNA polymerase.
incidence of GVHD, but most of these do result in eventual full donor chimerism. Means to suppress the donor contribution to chimerism and GVHD manifestations still remain unsatisfactory once engraftment and full chimerism are established. Thus, there appear to be states where mixed chimerism results in a peaceful state with no GVHD and no graft rejection with possible continued presence of a graftvs-tumor effect. In other cases, however, a state of mixed chimerism can be associated with host-vs-graft effects and risk for rejection and, possibly, for increased risk of disease relapse. Improved sensitivity of chimerism assays, increased use of lineage-specific chimerism and a better sense of the appropriate timing of the use of chimerism testing post transplantation may allow resolution of some of the controversy regarding the significance of a mixed chimeric state. At this point in time, available technologies to determine chimerism do not always allow for distinguishing between the absence of engraftment or delayed engraftment or between disease relapse and delayed graft rejection. Being able to understand whether the state of mixed chimerism will remain stable, will indicate disease evolution or will herald graft rejection will be of importance. This is especially important because states of mixed chimerism are often associated with less GVHD, and in the absence of disease relapse, there would not necessarily be added benefit to DLIs that could pose increased risk of severe GVHD. Timely use of lineage-specific chimerism assays with sensitive means to detect minimal residual disease will therefore offer important insights to improve therapeutic benefit of stem cell transplants in the future when studied prospectively in large groups of patients with uniform disease states and uniform transplantation regimens.
Future directions
In addition to understanding the significance of early T-cell chimerism and standardizing sampling frequency and methodologies by which this is established, increased knowledge of which T-cell subsets are important for tolerance induction and maintenance of graft vs malignancy effects without exacerbation of GVHD will be necessary to develop improved strategies to generate grafts that have adequate proportions of these T cells with the capability of homing and expansion, with the ultimate goal of achieving lasting stable mixed chimerism. For example, selective expansion of T-reg cells might allow establishment of a state of tolerance with preservation of any needed graft vs malignancy effect. In addition, better understanding of the effect that conditioning regimens have on donor T-cell and DC subset survival will allow tailoring of these regimens to create states conducive to mixed chimerism to reduce GVHD, yet maintaining host tolerance to the stem cell graft. Further knowledge of how other graft components such as mesenchymal stem cells might contribute to T-cell chimerism is also important to develop not only in relation to hematopoietic SCT but also to situations where these cells might be utilized for tissue repair. Understanding how to achieve mixed chimerism or split chimerism of DCs that mediate GVHD in various organs targeted by GVHD 84 will also be of importance.
Through the use of MoAbs or other selection markers to isolate and to expand appropriate cell subsets, it may be possible in certain diseases to create degrees of mixed chimerism that would assure allograft survival yet induce states of tolerance. This knowledge will also be of use in the future to facilitate a better understanding of the role of maternal microchimerism in tolerance and autoimmune disease, 85 as well as in the immunogenicity of and immune response to cells derived from embryonic stem cells and stem cells from other tissues should these be used in therapeutic settings in the future. 86 
